Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
techcrunch.comMarina Temkin
Enveda, an AI biotech company, raised $311 million in funding at a $2 billion valuation to advance nature-derived drug candidates into clinical trials. The company is developing treatments for skin conditions and weight loss maintenance following GLP-1 therapy discontinuation.
Why it mattersThis funding signals investor confidence in AI-driven drug discovery from natural sources, potentially expanding treatment options beyond synthetic pharmaceuticals. Readers interested in biotech applications of AI now have a concrete example of how the technology moves from research to clinical stage.
From the source: The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.Read at techcrunch.com